PONTE VEDRA, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Tuesday, November 5, 2024. Company management will host a conference call to d ...

Core Viewpoint - Treace Medical Concepts, Inc. has filed a lawsuit against Stryker Corporation and its subsidiary Wright Medical Technology, alleging infringement of 9 patents related to its Lapiplasty® 3D Bunion Correction® technologies and unfair competition [1][2]. Company Overview - Treace Medical Concepts is a medical technology company focused on advancing the surgical treatment of bunions and related midfoot deformities, with its flagship products being the Lapiplasty® and Adductoplasty® Procedures [1][4]. - The company estimates that approximately 67 million Americans are affected by bunions, with around 1.1 million being annual surgical candidates [4]. Patent and Legal Actions - The lawsuit seeks injunctive relief and damages, emphasizing Treace's commitment to protecting its intellectual property and investments in research and technology [1][2]. - Treace claims to be the first company to develop and patent an instrumented 3D bunion correction system, which has established a new segment in the US bunion market [2]. Financial Expectations - The company anticipates a 50% improvement in Adjusted EBITDA for 2024 compared to the full-year 2023 and expects to reach Adjusted EBITDA breakeven in 2025 [2].

PONTE VEDRA, Fla., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies at the American Orthopaedic Foot & Ankle Societ ...

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.20 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -17.24%. A quarter ago, it was expected that this orthopedic medical device maker would post a loss of $0.30 per share when it actually produced a loss of $0.30, delivering no surprise. Over the last four quarters ...

Core Viewpoint - Treace Medical Concepts, Inc. reported a 6% increase in revenue for Q2 2024, driven by a shift in product mix and an expanding active surgeon base, while also reaffirming its full-year revenue guidance of $201 million to $211 million, indicating growth of 7% to 13% compared to 2023 [2][3][8]. Financial Performance - Revenue for Q2 2024 was $44.5 million, up from $42.0 million in Q2 2023, reflecting a 6% increase [3]. - Gross profit for Q2 2024 was $35.7 million, compared to $34.3 million in Q2 2023, with a gross margin of 80.2%, down from 81.7% in the previous year [4]. - Total operating expenses rose to $57.1 million in Q2 2024 from $47.3 million in Q2 2023, attributed to strategic investments and increased share-based compensation [5]. Net Loss and Adjusted EBITDA - The net loss attributable to common stockholders for Q2 2024 was ($21.2) million, or ($0.34) per share, compared to a net loss of ($12.3) million, or ($0.20) per share, in Q2 2023 [6][19]. - Adjusted EBITDA loss was ($8.7) million in Q2 2024, compared to a loss of ($7.7) million in Q2 2023 [6]. Cash Position - As of June 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $97.0 million, indicating sufficient balance sheet strength to support ongoing strategic investments [7]. Patent Portfolio - The company expanded its patent portfolio to 65 granted U.S. patents, with an additional 22 granted patents worldwide and 84 pending U.S. patent applications, enhancing its competitive position in the market [2]. Future Outlook - The company plans to launch several new products in the second half of 2024, including entry into the minimally invasive metatarsal osteotomy market, aiming to capture a larger share of procedure volumes [2][8].

Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company's investor relations website at https://investors.treace.com/. Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. ...

Core Insights - Treace Medical Concepts, Inc. is participating in a fireside chat at the Truist Securities MedTech Conference on June 18, 2024, featuring CEO John T. Treace and CFO Mark L. Hair [1] Company Overview - Treace Medical Concepts is focused on advancing surgical treatment for bunions and related midfoot deformities, with its flagship procedures being Lapiplasty® and Adductoplasty® [4] - Approximately 67 million Americans are affected by bunions, with an estimated 1.1 million being annual surgical candidates [4] - The company has developed the Lapiplasty® 3D Bunion Correction® System, which addresses the root cause of bunions by correcting deformities in all three planes and stabilizing the affected joint [4] - Treace has also introduced the Adductoplasty® Midfoot Correction System and the Hammertoe PEEK Fixation System to address various foot deformities [4] - The company is expanding its product offerings with the SpeedPlate™ Rapid Compression Implants, which provide versatile fixation options for various surgical procedures [4]

NEW YORK, May 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ: TMCI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Treace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 7, 2024 ...

Treace Medical Concepts Inc (NASDAQ:TMCI) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Julie Dewey - Chief Communications & Investor Relations Officer John Treace - Founder & CEO Mark Hair - Chief Financial Officer Conference Call Participants Richard Newitter - Truist Securities Drew Ranieri - Morgan Stanley Harrison Parsons - Stephens Simon Nigan - UBS Operator Good day, and thank you for standing by, and welcome to the Treace Medical Concepts First Quarter 2024 Earnings Co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40355 Treace Medical Concepts, Inc. (Exact name of registrant as specified in its charter) Delaware 47-1052611 (State or ...